Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and
anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and
other inflammatory disorders of the retina, choroid and vitreous.